Sale

Bronchial Spasms Treatment Market

Global Bronchial Spasms Treatment Market Share, Analysis, Trends, Forecast: By Diagnosis Type: Imaging Test, Spirometry Test, Others; By Treatment Type: Short-Acting Bronchodilators, Long-Acting Bronchodilators, Inhaled Steroids, Oral or Intravenous Steroids; By Distribution Channel; Regional Analysis; Supplier Landscape; 2024-2032

Global Bronchial Spasms Treatment Market Outlook

The rising prevalence of asthma drives the value of the bronchial spasms treatment market size. The number of asthma cases was nearly 306.09 million in 2023. The prevalence of the disease is likely to grow at a rate of 4.0% in the forecast period of 2024-2032. With this growth rate, the number of cases expected in 2032 is approximately 435.67 million.

 

bronchial spasms treatment market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Bronchial Spasms: Disease and Treatment Outlook

Bronchial spasms are among the most common pulmonary disorders. In bronchial spams, the muscles around the bronchial tubes contract or inflame and obstruct the airway flow. This leads to irregular or short breathing and, in extreme situations, can lead to death.

 

The most common symptoms of bronchial spasms include wheezing, pain in the chest, difficulty in breathing and coughing. The contraction and inflammation of bronchial muscles are due to the associated pulmonary disorders like emphysema, asthma, bronchitis, or chronic obstructive pulmonary disease (COPD). 

 

Bronchial spasms are likely to affect children, older adults, and people with weakened immune systems. People suffering from other allergies like food allergies or eczema are also expected to develop bronchial spasms.

 

Diagnosis and Therapeutic Interventions

Early diagnosis of bronchial spasms is important for proper therapeutic intervention. The diagnosis is done using tests like CT scans, chest X-rays, mucus testing or other imaging tests. Spirometry is an important diagnostic test used to measure the amount of air inhaled and exhaled through the lungs.

 

Treatment interventions for bronchial spasms depend on the pathophysiology and the severity of the disease. The effective treatment strategies are administering inhaled steroids, use of , and changes in lifestyle patterns.

 

According to the bronchial spasms treatment market research report, the market can be categorised into the following segments:

 

bronchial spasms treatment market by segments

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Market Breakup by Diagnosis Type

  • Imaging Test
  • Spirometry Test
  • Others

 

Market Breakup by Treatment Type

  • Short-acting Bronchodilators
    • Levalbuterol (Xopenex, Xopenex HFA)
    • Albuterol (AccuNeb, Proventil HFA, ProAir HFA, Ventolin HFA)
  • Long-acting Bronchodilators
    • Aclidinium (Tudorza)
    • Arformoterol (Brovana)
    • Formoterol (Foradil, Perforomist)
    • Glycopyrrolate (Seebri Neohaler)
    • Indacaterol (Arcapta)
    • Olodaterol (Striverdi Respimat)
    • Salmeterol (Serevent)
    • Tiotropium (Spiriva)
  • Inhaled Steroids
    • Salbutamol
  • Oral or Intravenous Steroids

 

Bronchial Spasms Treatment Market Breakup by Distribution Channel

  • Hospitals
  • Diagnostic Centres
  • Clinics
  • Others

 

Market Breakup by Region

  • North America
    • United States of America
    • Canada
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Others
  • Asia Pacific
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • Others
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • United Arab Emirates
    • Nigeria
    • South Africa
    • Others

 

bronchial spasms treatment market by region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Bronchial Spasms Treatment Market Scenario

The bronchial spasms treatment market is driven by the increasing prevalence and incidence of respiratory disorders like emphysema, asthma, chronic bronchitis, and chronic obstructive pulmonary disorder. In 2021, around 283 million people were diagnosed with asthma, which is why there is more demand for more air inhalers, facilitating market growth.

 

Technological advancements are one of the primary drivers attributing to the development of the market. Healthcare products are getting better and better with the rapidly evolving innovative technologies. For example, with the invention of smart inhalers, patients can poise their dosage and take it according to their suitability.

 

The additional factors supplementing the market growth include rising adoption of IoT devices, increasing geriatric population, and increased investments by the key players.

 

Short-Acting Bronchodilators Hold the Largest Share

Short-acting bronchodilators account for the largest share of the global market. This can be attributed to its immediate therapeutic effect in treating acute or chronic bronchial spasms.

 

North America is Anticipated to be the Dominant Regional Market

North America will hold a significant share of the bronchial spasms treatment market. This is due to the technological advancements, rising geriatric population, increasing awareness and more research and developmental activities.

 

Therapeutic Landscape

There are several treatment strategies for the management of bronchial spasms. Through diagnostic studies, the healthcare provider provides the best possible treatment. The treatment of bronchospasms is done with bronchodilators. The bronchodilators are administered through air inhalers, nebulisers, or tablet dosage forms.

 

Potent Remedies

The bronchodilator type is prescribed to assess the extremity of the situation. Short-acting bronchodilators are generally defined in case of immediate or rapid effects. This type of medication can open the blocked pathways within minutes. Some examples of these medications are Levalbuterol and Albuterol.

 

The long-acting bronchodilators take longer time to show their therapeutic effects but effectively reduces the risk of bronchospasms in the near future. Some long-acting bronchodilators are Aclidinium, Arformoterol, Formoterol, Glycopyrrolate, Indacaterol, Olodaterol, Salmeterol, and Tiotropium.

 

In case of severe or chronic bronchitis, inhaled steroids are incorporated as a therapeutic intervention. The steroids reduce the inflammation around the bronchial muscles. The oral and intravenous routes are the optimal administration routes for steroids.

 

Tremendous efforts of scientists, researchers, and healthcare professionals will lead to innovative therapies that will lay the foundation for next-generation technologies. 

 

Henceforth, all these novel treatments will help improve healthcare and the global economy. These new treatment strategies will majorly drive the growth of the global bronchial spasms treatment market in the forecast period.

 

Clinical Trial Landscape

With extensive research and development, novel treatment methods are being discovered, projected to boost the growth of the bronchial spasms treatment market. During the clinical trials, combination therapies proved excellent treatment sources due to their synergistic therapeutic action.

 

Novel Targeted Therapies and Programs

Incorporating two monotherapies, inhaled corticosteroids, and short-acting beta two agonists as a single combined therapy will provide dual therapeutic action. The corticosteroids help reduce inflammation in bronchial airways and potentiate short-acting bronchodilators' therapeutic response.  

 

In 2023, Pantherics Inc., a key player, received funds of USD 255,000 from the National Institutes of Health. This will facilitate the clinical trials for a novel bronchospasms drug that will be used to manage asthma and other pulmonary disorders.

 

The clinical trials are also done to increase patient awareness and adherence to the prescribed medication schedule. For example, in 2023, Boehringer Ingelheim Pharmaceuticals and HealthPrize conducted a program to educate chronic obstructive pulmonary disorder patients about medication adherence. 

 

Implementing technology in healthcare has already provided enormous benefits to human health. Researchers’ tremendous efforts have anticipated a rapid increase in the approvals for bronchial spasms therapies. Several ongoing clinical trials are emerging as a key driving factor for market growth and development.

 

Competitive Landscape

The report gives an in-depth analysis of the key players involved in the bronchial spasms treatment market, sponsors manufacturing the therapies, and putting them through trials to get FDA approvals. The companies included in the market are as follows:

  • Novartis International AG
  • GSK plc
  • Merck & Co., Inc.
  • AstraZeneca plc
  • C. H. Boehringer Sohn Co. KG
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Sunovion Pharmaceuticals Inc.
  • Amphstar Pharmaceuticals, Inc.
  • Pfizer, Inc.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Diagnosis Type
  • Treatment Type
  • Distribution Channel
  • Region
Breakup by Diagnosis Type
  • Imaging Test
  • Spirometry Test
  • Others
Breakup by Treatment Type
  • Short-Acting Bronchodilators
  • Long-Acting Bronchodilators
  • Inhaled Steroids
  • Oral or Intravenous Steroids
Breakup by Distribution Channel
  • Hospitals
  • Diagnostic Centres
  • Clinics
  • Others
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • Market Drivers and Constraints
  • SWOT
  • Porter's Five Forces
  • Key Indicators for Demand
  • Key Indicators for Price
  • Industry Events, Initiatives, and Trends
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Company Overview
    • Product Portfolio
    • Demographic Reach and Achievements
    • Certifications
Companies Covered
  • Novartis International AG
  • GSK plc
  • Merck & Co., Inc.
  • AstraZeneca plc
  • C. H. Boehringer Sohn Co. KG
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Sunovion Pharmaceuticals Inc.
  • Amphstar Pharmaceuticals, Inc.
  • Pfizer, Inc.

 

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions
    1.3    Report Coverage – Key Segmentation and Scope 
2    Research Methodology
3    Executive Summary
4    Bronchial Spasms Overview

    4.1    Guidelines and Stages
    4.2    Pathophysiology
    4.3    Screening and Diagnosis
    4.4    Treatment Pathway 
5    Patient Profile
    5.1    Patient Profile Overview
    5.2    Patient Psychology and Emotional Impact Factors
    5.3    Risk Assessment and Treatment Success Rate
6    Current Scenario Evaluation and Regulatory Framework
    6.1    Emerging Therapies and Clinical Trials
    6.2    Patent Landscape 
        6.2.1    Patent Overview
            6.2.1.1    Patent Status and Expiry
            6.2.1.2    Timelines from Drug Development to Commercial Launch
            6.2.1.3    New Drug Application
                6.2.1.3.1    Documentation and Approval Process
    6.3    Cost of Treatment
    6.4    Regulatory Framework
        6.4.1    Regulatory Overview
            6.4.1.1    US FDA
            6.4.1.2    EU EMA
            6.4.1.3    INDIA CDSCO
            6.4.1.4    JAPAN PMDA
            6.4.1.5    Others
7    Challenges and Unmet Needs
    7.1    Treatment Pathway Challenges
    7.2    Compliance and Drop-Out Analysis
    7.3    Awareness and Prevention Gaps
8    Global Bronchial Spasms Treatment Market
    8.1    Global Bronchial Spasms Treatment Market Overview
    8.2    Global Bronchial Spasms Treatment Market Analysis 
        8.2.1    Market Overview
            8.2.1.1    Global Bronchial Spasms Treatment Market Historical Value (2017-2023) 
            8.2.1.2    Global Bronchial Spasms Treatment Market Forecast Value (2024-2032)
        8.2.2    Global Bronchial Spasms Treatment Market by Diagnosis Type
            8.2.2.1    Market Overview
                8.2.2.1.1    Imaging Test
                8.2.2.1.2    Spirometry Test
                8.2.2.1.3    Others
        8.2.3    Global Bronchial Spasms Treatment Market by Treatment Type
            8.2.3.1    Market Overview
                8.2.3.1.1    Short-Acting Bronchodilators
                    8.2.3.1.1.1    Levalbuterol (Xopenex, Xopenex HFA)
                    8.2.3.1.1.2    Albuterol (AccuNeb, Proventil HFA, ProAir HFA, Ventolin HFA)
                8.2.3.1.2    Long-Acting Bronchodilators
                    8.2.3.1.2.1    Aclidinium (Tudorza)
                    8.2.3.1.2.2    Arformoterol (Brovana)
                    8.2.3.1.2.3    Formoterol (Foradil, Perforomist)
                    8.2.3.1.2.4    Glycopyrrolate (Seebri Neohaler)
                    8.2.3.1.2.5    Indacaterol (Arcapta)
                    8.2.3.1.2.6    Olodaterol (Striverdi Respimat)
                    8.2.3.1.2.7    Salmeterol (Serevent)
                    8.2.3.1.2.8    Tiotropium (Spiriva)
                8.2.3.1.3    Inhaled Steroids
                    8.2.3.1.3.1    Salbutamol
                8.2.3.1.4    Oral or Intravenous Steroids
        8.2.4    Global Bronchial Spasms Treatment Market by Distribution Channel 
            8.2.4.1    Market Overview
                8.2.4.1.1    Hospitals
                8.2.4.1.2    Diagnostic Centres
                8.2.4.1.3    Clinics
                8.2.4.1.4    Others
        8.2.5    Global Bronchial Spasms Treatment Market by Region
            8.2.5.1    Market Overview
                8.2.5.1.1    North America
                8.2.5.1.2    Europe
                8.2.5.1.3    Asia Pacific
                8.2.5.1.4    Middle East and Africa
                8.2.5.1.5    Latin America
9    North America  Bronchial Spasms Treatment Market
    9.1    Market Share by Country
    9.2    United States of America
        9.2.1    Historical Trend (2017-2023)
        9.2.2    Forecast Trend (2024-2032)
    9.3    Canada
        9.3.1    Historical Trend (2017-2023)
        9.3.2    Forecast Trend (2024-2032)
10    Europe Bronchial Spasms Treatment Market
    10.1    Market Share by Country
    10.2    United Kingdom
        10.2.1    Historical Trend (2017-2023)
        10.2.2    Forecast Trend (2024-2032)
    10.3    Germany
        10.3.1    Historical Trend (2017-2023)
        10.3.2    Forecast Trend (2024-2032)
    10.4    France
        10.4.1    Historical Trend (2017-2023)
        10.4.2    Forecast Trend (2024-2032)
    10.5    Italy
        10.5.1    Historical Trend (2017-2023)
        10.5.2    Forecast Trend (2024-2032)
    10.6    Others
11    Asia Pacific Bronchial Spasms Treatment Market
    11.1    Market Share by Country
    11.2    China
        11.2.1    Historical Trend (2017-2023)
        11.2.2    Forecast Trend (2024-2032)
    11.3    Japan
        11.3.1    Historical Trend (2017-2023)
        11.3.2    Forecast Trend (2024-2032)
    11.4    India
        11.4.1    Historical Trend (2017-2023)
        11.4.2    Forecast Trend (2024-2032)
    11.5    ASEAN
        11.5.1    Historical Trend (2017-2023)
        11.5.2    Forecast Trend (2024-2032)
    11.6    Australia
        11.6.1    Historical Trend (2017-2023)
        11.6.2    Forecast Trend (2024-2032)
    11.7    Others
12    Latin America Bronchial Spasms Treatment Market
    12.1    Market Share by Country
    12.2    Brazil
        12.2.1    Historical Trend (2017-2023)
        12.2.2    Forecast Trend (2024-2032)
    12.3    Argentina
        12.3.1    Historical Trend (2017-2023)
        12.3.2    Forecast Trend (2024-2032)
    12.4    Mexico
        12.4.1    Historical Trend (2017-2023)
        12.4.2    Forecast Trend (2024-2032)
    12.5    Others
13    Middle East and Africa Bronchial Spasms Treatment Market
    13.1    Market Share by Country
    13.2    Saudi Arabia
        13.2.1    Historical Trend (2017-2023)
        13.2.2    Forecast Trend (2024-2032)
    13.3    United Arab Emirates
        13.3.1    Historical Trend (2017-2023)
        13.3.2    Forecast Trend (2024-2032)
    13.4    Nigeria
        13.4.1    Historical Trend (2017-2023)
        13.4.2    Forecast Trend (2024-2032)
    13.5    South Africa
        13.5.1    Historical Trend (2017-2023)
        13.5.2    Forecast Trend (2024-2032)
    13.6    Others
14    Global Bronchial Spasms Treatment Market Dynamics
    14.1    Market Drivers and Constraints
    14.2    SWOT Analysis
    14.3    Porter’s Five Forces Model 
    14.4    Key Demand Indicators 
    14.5    Key Price Indicators 
    14.6    Industry Events, Initiatives, and Trends 
    14.7    Value Chain Analysis
15    Supplier Landscape
    15.1    Novartis International AG
        15.1.1    Company Overview
        15.1.2    Product Portfolio
        15.1.3    Demographic Reach and Achievements
        15.1.4    Mergers and Acquisitions
        15.1.5    Certifications
    15.2    GSK plc
        15.2.1    Company Overview
        15.2.2    Product Portfolio
        15.2.3    Demographic Reach and Achievements
        15.2.4    Mergers and Acquisitions
        15.2.5    Certifications
    15.3    Merck & Co., Inc.
        15.3.1    Company Overview
        15.3.2    Product Portfolio
        15.3.3    Demographic Reach and Achievements
        15.3.4    Mergers and Acquisitions
        15.3.5    Certifications
    15.4    AstraZeneca plc
        15.4.1    Company Overview
        15.4.2    Product Portfolio
        15.4.3    Demographic Reach and Achievements
        15.4.4    Mergers and Acquisitions
        15.4.5    Certifications
    15.5    C. H. Boehringer Sohn Co. KG
        15.5.1    Company Overview
        15.5.2    Product Portfolio
        15.5.3    Demographic Reach and Achievements
        15.5.4    Mergers and Acquisitions
        15.5.5    Certifications
    15.6    Teva Pharmaceutical Industries Ltd.
        15.6.1    Company Overview
        15.6.2    Product Portfolio
        15.6.3    Demographic Reach and Achievements
        15.6.4    Mergers and Acquisitions
        15.6.5    Certifications
    15.7    Viatris Inc.
        15.7.1    Company Overview
        15.7.2    Product Portfolio
        15.7.3    Demographic Reach and Achievements
        15.7.4    Mergers and Acquisitions
        15.7.5    Certifications
    15.8    Sunovion Pharmaceuticals Inc.
        15.8.1    Company Overview
        15.8.2    Product Portfolio
        15.8.3    Demographic Reach and Achievements
        15.8.4    Mergers and Acquisitions
        15.8.5    Certifications
    15.9    Amphstar Pharmaceuticals, Inc.
        15.9.1    Company Overview
        15.9.2    Product Portfolio
        15.9.3    Demographic Reach and Achievements
        15.9.4    Mergers and Acquisitions
        15.9.5    Certifications
    15.10    Pfizer, Inc.
        15.10.1    Company Overview
        15.10.2    Product Portfolio
        15.10.3    Demographic Reach and Achievements
        15.10.4    Mergers and Acquisitions
        15.10.5    Certifications
16    Global Bronchial Spasms Treatment Market- Drug Distribution Model (Additional Insight)
    16.1    Overview 
    16.2    Potential Distributors 
    16.3    Key Parameters for Distribution Partner Assessment
17    Payment Methods (Additional Insight)
    17.1    Government Funded
    17.2    Private Insurance
    17.3    Out-of-Pocket

 

*Additional insights provided are customisable as per client requirements.

Key Questions Answered in the Report

Bronchodilators are the medications used for widening the obstructed or blocked bronchial pathways and thus helps in normal breathing.

Increasing prevalence of pulmonary disorders, technological advancements, increased research and developmental activities, and better awareness are the driving factors of the market.

Based on the diagnosis type, the market is segmented into spirometry tests and imaging tests, among others.

Based on the treatment type, the market is categorised into long-acting bronchodilators, short acting bronchodilators, inhaled steroids, and oral or intravenous steroids.

The distribution channels in the market are hospitals, diagnostic centres, and clinics, among others.

The different regions in the market are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. North America is anticipated to hold a significant share of the market during the forecast period.

The bronchodilators help manage obstruction and inflammation of bronchial muscles caused due to the associated pulmonary disorders like emphysema, asthma, bronchitis, or chronic obstructive pulmonary disease (COPD).

The key companies involved in the market are Novartis International AG, GSK plc, Merck & Co., Inc., AstraZeneca plc, C. H. Boehringer Sohn Co. KG, Teva Pharmaceutical Industries Ltd., Viatris Inc., Sunovion Pharmaceuticals Inc., Amphstar Pharmaceuticals, Inc., and Pfizer, Inc., among others.

Purchase Full Report

Mini Report

$ 3499     $2999
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 5999     $5499
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 8299     $7499
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 10499     $9499
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER